Drug Trial Radar · NCT06475001
Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain
Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
652
Actual
Start
Jun 28, 2024
Primary completion
Jul 31, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Vertanical GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dose-response characterization of VER-01 in patients with chronic non-specific low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
Conditions
- Chronic Non-specific Low Back Pain
Interventions
VER-01Drug
Herbal medicinal product, containing as active substance a soft extract of Cannabis sativa L., cannabis flos (Cannabis flower), adjusted to a content of 50 mg/g delta-9-tetrahydrocannabinol (THC). VER-01 is adjusted to a concentration of 19 mg/mL THC by adding the excipient sesame oil.
PlaceboDrug
Comparator without active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy based on pain reductionTime frame: End of the Treatment Phase (Week 7) compared to Baseline (Week -1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St Pancras Clinical Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.